Maria Matilde I.
- Country
- Italy
- Department
- Neurologia
Research Overview
- Phase III Randomized Double‑Blind Study of Fenebrutinib versus Teriflunomide for Efficacy and Safety in Adults with Relapsing Multiple Sclerosis
- Phase 3 Randomized Double-Blind Study of Orelabrutinib for Primary Progressive Multiple Sclerosis in Patients With PPMS
- Phase 3 Randomized, Double-Blind Study of Frexalimab (SAR441344) Versus Teriflunomide in Adults with Relapsing Multiple Sclerosis
Data & Insights
Has run more than one trial at 180 of 366 partner sites.
Specializations
Multiple Sclerosis Treatment
This investigator specializes in researching innovative therapeutic approaches for multiple sclerosis (MS), with particular emphasis on both relapsing and progressive forms of the disease.
- Relapsing Multiple Sclerosis (RMS)
- Primary Progressive Multiple Sclerosis (PPMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
The research includes evaluation of novel therapeutic agents and their effects on disease progression and inflammation.
Advanced Therapeutic Approaches
The investigator focuses on cutting-edge treatment modalities including autologous hematopoietic stem cell transplantation and peptide-coupled red blood cell therapies.
- Cell-based Therapies
- Targeted Immunological Treatments
- Novel Therapeutic Compounds
Research extends to investigating disease activity markers and therapeutic responses in MS patients.
Early Disease Detection
The investigator conducts research in early-stage MS detection, particularly focusing on Radiologically Isolated Syndrome (RIS) and preventive interventions.
- Magnetic Resonance Imaging Studies
- Disease Activity Monitoring
- Preventive Treatment Approaches
The work includes evaluation of neurological markers and imaging techniques for disease monitoring.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.